Completed PHASE2 INTERVENTIONAL 3-arm NCT02960815

Imiquimod and Influenza Vaccine for Immunocompromised Patients (IMIFLU)

Safety and Immunogenicity of Seasonal Influenza Vaccine With Topical Imiquimod in Immunocompromised Patients: A Randomized Controlled Pilot Trial

Sponsor: University of Lausanne Hospitals

Conditions Influenza Vaccine

Interventions Aldara Intanza Mutagrip

Updated 6 times since 2017 Last updated: Oct 9, 2017 Started: Nov 30, 2016 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Influenza Vaccine, this trial is completed. The trial is conducted by University of Lausanne Hospitals and has accumulated 6 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Oct 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Oct 2017 [monthly]

Recruiting PHASE2

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Lausanne Hospitals

Data source: University of Lausanne Hospitals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lausanne, Switzerland